AACR 2023 | What role will ADCs play in the prostate cancer treatment landscape?

So, I think there’s a bright future for antibody drug conjugates in oncology period, but also in prostate cancer. So, there’s a number of different cell surface targets that lend themselves well, obviously the first cell surface target to really lead to approval, not an antibody drug conjugate but at least kind of validated that or de-risk it as PSMA. We’ve seen some interesting early phase data for B7-H3. A couple of different companies have ADCs against that and there’s a number of others that are out there, actually expanding cell surface targeting in general, whether it’s an antibody drug conjugate, whether it is a bispecific or CAR-T-cell or whether it is a radiolabeled kind of a targeting vector with STEEP1, DLL3, PSCA, I’m missing a lot of other ones. TROP2 is in Phase II. So there’s a number of other ones that are that are out there and you know, not unique to prostate cancer but as an epithelial type of a tumor, as well as actually what’s true in malignancies, is that there are some cell surface targets that are either fairly unique to prostate cancer or are differential in terms of the amount of expression that can be exploited by different types of compounds, including antibody drug conjugates. I think we are now at the stage where we have much better linker technology than we had before as well as a number of different payloads. Most commonly it’s going to be something that’s targets DNA or microtubules, but I think we can also move beyond those. Both of those have shown some efficacy in prostate cancers mechanisms, so I think that’s also nice.